Table 1 |
||
|
Demographic and clinical features of 141 patients with primary Sjögren syndrome |
||
| Number |
Percentage |
|
|
|
||
| Females/Males |
114/27 |
80.9/19.1 |
| Age (range), years |
48 (39–60) |
|
| Median disease duration (IQR), years |
2.49 (0.98–6.12) |
|
| Synovitis (objective swelling) |
44 |
31.2 |
| Extra-glandular involvement (skin, lung, kidney, or vasculitis) |
81 |
57.4 |
| Median erythrocyte sedimentation rate (IQR), mm/1st hour |
27 (17–38) |
|
| Median C-reactive protein (IQR), mg/dL |
0.57 (0.31–0.9) |
|
| Rheumatoid factor |
94 |
66.7 |
| Anti-CCP antibodies |
14 |
9.9 |
| Anti-nuclear antibodies |
134 |
95 |
| Anti-La (SSB) antibodies |
55 |
39.1 |
| Anti-Ro (SSA) antibodies |
115 |
81.6 |
| Focus score of greater than 1 |
94 |
67.1 |
|
|
||
|
Demographic characteristics and continuous data are expressed as median (interquartile range, IQR). Categorical data are expressed as absolute frequency and percentage. Anti-CCP, cyclic citrullinated peptide antibody. |
||
|
Atzeni et al. Arthritis Research & Therapy 2008 10:R51 doi:10.1186/ar2420 |
||
